Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_4
1
25%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

recruiting125%
completed250%
not_yet_recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
not_yet_recruiting

Clinical Utility of Urinary N-Acetyl-β-D-Glucosaminidase (NAG), Kidney Injury Molecule-1 (KIM-1), and Diffusion-Weighted Renal MRI for the Early Detection of Sickle Cell Nephropathy in Children

NCT07785752
recruitingnot_applicable

Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia

NCT07673302
completedphase_4

Efficacy of Combination of Hdroxyurea and Thalidomide Over Hydroxyurea or Thalidomide in the Treatment of Transfusion Dependent Thalassemia in Children

NCT06299670
completedphase_2

Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

NCT04301336

Clinical Trials (4)

Showing 4 of 4 trials
NCT07785752

Clinical Utility of Urinary N-Acetyl-β-D-Glucosaminidase (NAG), Kidney Injury Molecule-1 (KIM-1), and Diffusion-Weighted Renal MRI for the Early Detection of Sickle Cell Nephropathy in Children

Not Yet Recruiting
NCT07673302Not Applicable

Safety and Efficacy of Hemoglobin F Inducers in Patients With Beta Thalassemia

Recruiting
NCT06299670Phase 4

Efficacy of Combination of Hdroxyurea and Thalidomide Over Hydroxyurea or Thalidomide in the Treatment of Transfusion Dependent Thalassemia in Children

Completed
NCT04301336Phase 2

Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4